NICE reprieve for Alimera's Iluvien
This article was originally published in Scrip
Alimera Sciences' Iluvien (fluocinolone acetonide intravitreal implant) is a step away from winning final and binding endorsement from England's health technology appraisal institute, NICE, for the treatment of chronic diabetic macular edema that does not respond to available treatments. The institute has published final draft guidance recommending the drug.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.